PLPC-NX | Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

452 results for “PLPC-NX”

Trials

View all 124 →

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

572 participants · First posted Nov 23, 2021

A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies

248 participants · First posted Apr 2, 2021

A Study of NX-1607 in Adults With Advanced Malignancies

345 participants · First posted Nov 4, 2021

Drugs

View all 210 →

NX-9

NX-020

NX-08

Organizations

View all 69 →

NX DEVELOPMENT CORP

United States

PSF, PLLC.

United States

DERM RESEARCH PLLC

United States

News

View all 49 →

OGRD Alliance Expands Phospholipoproteomic Platform Across Asia and MENA Regions

OGRD Alliance Announces PLPC-DB Non-Cellular Oncology Immunotherapy Platform for Global Acquisition

FDA Grants Fast Track Designation to Nurix Therapeutics' NX-5948 for Relapsed/Refractory CLL/SLL

Page 1 of 46